Watts, Gerald F. http://orcid.org/0000-0003-2276-1524
Schwabe, Christian http://orcid.org/0000-0002-3848-1132
Scott, Russell
Gladding, Patrick A.
Sullivan, David
Baker, John
Clifton, Peter
Hamilton, James
Given, Bruce
Melquist, Stacey http://orcid.org/0000-0002-2974-9635
Zhou, Rong
Chang, Ting
San Martin, Javier
Gaudet, Daniel
Goldberg, Ira J.
Knowles, Joshua W. http://orcid.org/0000-0003-1922-7240
Hegele, Robert A. http://orcid.org/0000-0003-2861-5325
Ballantyne, Christie M. http://orcid.org/0000-0002-6432-1730
Article History
Received: 23 September 2022
Accepted: 10 July 2023
First Online: 25 August 2023
Competing interests
: G.F.W. (corresponding author) reports personal fees for lectures from Amgen, Novartis and Sanofi; research grants from Amgen and Arrowhead Pharmaceuticals; and honoraria for serving on advisory boards from Amgen, AstraZeneca, Esperion, Novartis, Pfizer and Arrowhead Pharmaceuticals. J.H., B.G., S.M., J.S.M., T.C. and R.Z. are, or were recently, Arrowhead Pharmaceuticals employees and shareholders. I.G. reports being on advisory boards for Arrowhead Pharmaceuticals and Ionis. C.B. reports grant/research support (all substantial (>$10,000) and all paid to institution, not individual) from Akcea, Amgen, Arrowhead Pharmaceuticals, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron and National Institutes of Health and consultant for 89Bio, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Denka Seiken*, Eli Lilly, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi-Synthelabo (*substantial where noted). P.G. reports being principal investigator for Verve101 and receiving consulting fees from Verve Therapeutics. R.H. reports consulting fees from Acasti, Akcea/Ionis, Amgen, Amryt, Arrowhead Pharmaceuticals, Boston Heart, HLS Therapeutics, Pfizer, Novartis, Regeneron, Sanofi and Ultragenyx. D.G. reports grants and/or personal fees from Arrowhead Pharmaceuticals, Acasti, Amgen, Kowa, Regeneron, Uniqure, Akcea, Allergan, Amryt, CRISPR Therapeutics, Eli Lilly, Ionis, Novartis, Biogen, Sanofi, Novo Nordisk, Pfizer, Verve Therapeutics, Aegerion, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Ceapro, Dalcor, Esperion and The Medicine Company. D.S. reports honoraria for serving on advisory boards from Regeneron, Amgen, AstraZeneca, Amarin, Esperion, Novartis and Sanofi, outside the submitted work. No competing interests are reported by C.S., P.C., R.S., J.B. and J.K.